- Home
- PCSA vs TCRT Comparison
PCSA vs TCRT Comparison
Compare PCSA & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- TCRT
- Stock Information
- Founded
- PCSA 2011
- TCRT 1998
- Country
- PCSA United States
- TCRT United States
- Employees
- PCSA N/A
- TCRT N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- PCSA Health Care
- TCRT Health Care
- Exchange
- PCSA Nasdaq
- TCRT Nasdaq
- Market Cap
- PCSA 2.8M
- TCRT 2.5M
- IPO Year
- PCSA N/A
- TCRT N/A
- Fundamental
- Price
- PCSA $0.45
- TCRT $1.48
- Analyst Decision
- PCSA Strong Buy
- TCRT
- Analyst Count
- PCSA 1
- TCRT 0
- Target Price
- PCSA $6.00
- TCRT N/A
- AVG Volume (30 Days)
- PCSA 105.2K
- TCRT 9.9K
- Earning Date
- PCSA 03-28-2025
- TCRT 03-31-2025
- Dividend Yield
- PCSA N/A
- TCRT N/A
- EPS Growth
- PCSA N/A
- TCRT N/A
- EPS
- PCSA N/A
- TCRT N/A
- Revenue
- PCSA N/A
- TCRT $7,000.00
- Revenue This Year
- PCSA N/A
- TCRT N/A
- Revenue Next Year
- PCSA N/A
- TCRT N/A
- P/E Ratio
- PCSA N/A
- TCRT N/A
- Revenue Growth
- PCSA N/A
- TCRT N/A
- 52 Week Low
- PCSA $0.42
- TCRT $1.46
- 52 Week High
- PCSA $3.31
- TCRT $20.30
- Technical
- Relative Strength Index (RSI)
- PCSA 28.32
- TCRT 41.11
- Support Level
- PCSA $0.44
- TCRT $1.49
- Resistance Level
- PCSA $0.54
- TCRT $1.65
- Average True Range (ATR)
- PCSA 0.05
- TCRT 0.07
- MACD
- PCSA 0.00
- TCRT 0.00
- Stochastic Oscillator
- PCSA 16.03
- TCRT 9.09
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.